(Q42523512)

1 November 2017

title

Formation of pyridinium species of haloperidol in human liver and brain (English)

1 reference

1 November 2017

1 reference

2

1 reference

1 November 2017

D W Eyles

1

1 reference

1 November 2017

S M Pond

series ordinal

3

1 reference

1 November 2017

publication date

1 June 1996

1 reference

1 November 2017

1 reference

1 November 2017

volume

125

1 reference

1 November 2017

issue

3

1 reference

1 November 2017

page(s)

214-219

1 reference

Stereospecific reduction of haloperidol in human tissues

1 November 2017

cites work

1 reference

12 December 2020

Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes

1 reference

12 December 2020

Selective inhibitors of cytochromes P450.

1 reference

12 December 2020

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

1 reference

12 December 2020

Subcellular localization of cytochrome P450, and activities of several enzymes responsible for drug metabolism in the human brain

1 reference

12 December 2020

Nonlinear relationship between circulating concentrations of reduced haloperidol and haloperidol: evaluation of possible mechanisms

1 reference

12 December 2020

High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations

1 reference

12 December 2020

Reduced haloperidol in the post-mortem brains of haloperidol-treated patients

1 reference

12 December 2020

Use of antisera in the isolation of human specific conjugates of haloperidol

1 reference

12 December 2020

Determination of the pyridinium metabolite derived from haloperidol in brain tissue, plasma and urine by high-performance liquid chromatography with fluorescence detection

1 reference

12 December 2020

Haloperidol metabolism in psychiatric patients: importance of glucuronidation and carbonyl reduction

1 reference

12 December 2020

MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies

1 reference

12 December 2020

Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats

1 reference

12 December 2020

Metabolic studies on haloperidol and its tetrahydropyridine analog in C57BL/6 mice

1 reference

12 December 2020

Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds

1 reference

12 December 2020

1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies

1 reference

12 December 2020

Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite

1 reference

12 December 2020

Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene

1 reference

12 December 2020

Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450

1 reference

12 December 2020

Protein measurement with the Folin phenol reagent

1 reference

12 December 2020

Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia

1 reference

12 December 2020

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype

1 reference

12 December 2020

Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients

1 reference

12 December 2020

On the metabolism of haloperidol

1 reference

12 December 2020

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02247331

1 reference

Dimensions Publication ID

1 November 2017

1015024554

0 references

1 reference